Tier 3 — preclinical
Oral Supplementation with a New Hyaluronic Acid Matrix Ingredient Improves Skin Brightness, Hydration, Smoothness, and Roughness: Results from a Randomized, Double-Blinded, Placebo-Controlled Study
Dermatology and Therapy
2025
15:2099-2116
Bibliography
- PubMed
- PMID 40498387
- PubMed Central
- PMC12256382
- Trial registry
- View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
- Funding
- Funded by Bioiberica.
- Competing interests
- Three authors were full-time Bioiberica employees; the remaining authors declared nothing to disclose.
Study snapshot
| Design | Randomized, double-blind, placebo-controlled clinical trial |
|---|---|
| Model | Healthy women aged 35–65 with signs of natural skin aging |
| Sample | n=60 randomized; n=50 per-protocol analysis |
| Intervention | Dermial hyaluronic acid matrix 60 mg/day containing HA, sulfated glycosaminoglycans and collagen versus placebo |
| Duration | 12 weeks |
| Endpoints | Skin hydration; Brightness/glow; Wrinkles; Dryness; Roughness; Smoothness; Elasticity; pH; Erythema; Global satisfaction |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
